COMMUNIQUÉS West-GlobeNewswire

Alpha Tau Medical Announces Second Quarter 2024 Financial Results and Provides Corporate Update

14/08/2024 - 22:02

- First patient treated in May for liver metastases from colorectal cancer - - Publication in June in Cancers journal of long-term safety and efficacy data in multiple hard-to -treat superficial cancers , with an [...]

scPharmaceuticals Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

14/08/2024 - 22:01

Generated 2Q 2024 net FUROSCIX ® revenue of $8.1 million, up 33% sequentially from Q1 Completed financing that extends our cash runway through expected profitability Advanced multiple FUROSCIX growth initiatives [...]

Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update

14/08/2024 - 22:01

Announced plan to initiate Phase 3 VIKTORIA-2 trial evaluating gedatolisib combined with fulvestrant plus a CDK4/6 inhibitor as first-line treatment for patients with HR+, HER2- advanced breast cancer; expect to enroll [...]

Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer

14/08/2024 - 22:01

Overall response rate (“ORR”) of 25% and 50% disease control rate ("DCR") observed in first four evaluable patients treated with TIDAL-01 with advanced CRC Complete response achieved in heavily pre-treated late line [...]

American Shared Hospital Services Reports Strong Second Quarter 2024 Financial Results

14/08/2024 - 22:01

Revenue increases 27% year over year Reports gain of $3.7 million from strategic acquisition of Rhode Island Radiation Therapy Cancer Centers Now treating patients at the new Puebla, Mexico center Conference Call on [...]

ArriVent BioPharma Reports Second Quarter 2024 Financial Results

14/08/2024 - 22:01

Clinical proof-of-concept monotherapy data for once daily, first-line firmonertinib in EGFR PACC mutant non-small cell lung cancer (NSCLC) to be presented as a presidential symposium presentation at the 2024 World [...]

Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

14/08/2024 - 22:01

– Primary focus continues to be on upcoming results from ENLIGHTEN 1 Phase 3 extension study in 4Q 2024 and ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients in 1H 2025, as planned – – In parallel, the company continues [...]

Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights

14/08/2024 - 22:01

TX45 advances into Phase 2 clinical trial for patients with Group 2 PH-HFpEF with first site activated and screening open in August 2024 Received U.S. Investigational New Drug (IND) clearance for lead program, TX45 in [...]

NeuroOne® Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

14/08/2024 - 22:00

EDEN PRAIRIE, Minn., Aug. 14, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and [...]

Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update

14/08/2024 - 22:00

Second quarter net product revenues for ZORYVE ® franchise of $30.9M, with $17.3M for ZORYVE (roflumilast) cream 0.3%, and $13.6M for ZORYVE (roflumilast) topical foam, 0.3%; sales growth of 547% vs. Q2 '23 and 43% vs. [...]

Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic

14/08/2024 - 20:30

SP-26 dissolvable ketamine-based injectable implant targets chronic pain and fibromyalgia Sever Pharma to scale-up extrusion processes and continue analytical testing for novel non-opioid treatment SARASOTA, FL, Aug. 14 [...]

Decisely Celebrates its Place on the 2024 Inc. 5000 List of Fastest-Growing Private Companies

14/08/2024 - 20:30

ALPHARETTA, GA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Decisely, a leading provider of health benefits and management solutions for business owners, is proud to announce its inclusion in the prestigious Inc. 5000 list for [...]

SeaStar Medical Reports Second Quarter 2024 Financial Results and Provides a Business Update

13/08/2024 - 22:38

DENVER, Aug. 13, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary solutions to reduce the [...]

Guardion Health Sciences Announces Financial Results for the Three Months and Six Months Ended June 30, 2024

13/08/2024 - 22:35

Guardion Also Provides an Update to Stockholders of Significant Recent Developments HOUSTON, TEXAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a [...]

Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

13/08/2024 - 22:30

• AMPLIFY-7P Phase 1 preliminary disease-free (“DFS”) survival demonstrates strong correlation between T cell response and reduced risk of progression or death • AMPLIFY-7P Phase 1 data presented at ASCO demonstrated [...]

Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

13/08/2024 - 22:30

- Sutro will present updated data from the ongoing Phase 1b study of luvelta in combination with bevacizumab in a poster presentation at ESMO 2024; expansion study is ongoing with data expected in the first half of 2025 [...]

BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results

13/08/2024 - 22:30

SUNNYVALE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported [...]

Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

13/08/2024 - 22:29

SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies [...]

Bavarian Nordic Receives Order from HERA and Announces Significant Donation of Vaccines in Response to the Mpox Outbreak in Africa

13/08/2024 - 22:15

HERA will procure 175,420 doses for immediate response to the concerning mpox outbreak in Africa, and furthermore, Bavarian Nordic will donate 40,000 doses to HERA, also to be distributed to the Africa CDC. COPENHAGEN, [...]